EKF Diagnostics Holdings PLC
LSE:EKF
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EKF Diagnostics Holdings PLC
Current Portion of Long-Term Debt
EKF Diagnostics Holdings PLC
Current Portion of Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Current Portion of Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
EKF Diagnostics Holdings PLC
LSE:EKF
|
Current Portion of Long-Term Debt
£398k
|
CAGR 3-Years
-27%
|
CAGR 5-Years
-7%
|
CAGR 10-Years
-27%
|
|
|
Smith & Nephew PLC
LSE:SN
|
Current Portion of Long-Term Debt
$67m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
N/A
|
|
|
LivaNova PLC
NASDAQ:LIVN
|
Current Portion of Long-Term Debt
$31.5m
|
CAGR 3-Years
10%
|
CAGR 5-Years
19%
|
CAGR 10-Years
N/A
|
|
|
Creo Medical Group PLC
LSE:CREO
|
Current Portion of Long-Term Debt
£2.4m
|
CAGR 3-Years
-24%
|
CAGR 5-Years
69%
|
CAGR 10-Years
N/A
|
|
|
Inspiration Healthcare Group PLC
LSE:IHC
|
Current Portion of Long-Term Debt
£419k
|
CAGR 3-Years
-18%
|
CAGR 5-Years
34%
|
CAGR 10-Years
36%
|
|
|
EMV Capital PLC
LSE:EMVC
|
Current Portion of Long-Term Debt
£550k
|
CAGR 3-Years
164%
|
CAGR 5-Years
25%
|
CAGR 10-Years
N/A
|
|
EKF Diagnostics Holdings PLC
Glance View
EKF Diagnostics Holdings Plc is a vitro diagnostics company, which designs and manufactures diagnostic equipment for use within point-of-care settings. The company is headquartered in Penarth, South Glamorgan. The company went IPO on 2002-06-05. The firm's point-of-care range includes hemoglobin analyzers, HbA1c analyzers and glucose analyzers for use in the screening, monitoring and diagnosis of patients, as well as rapid tests for pregnancy and common infectious diseases. Its Central Laboratory division includes a range of products for use in both large and small laboratory facilities. Its subsidiary, EKF Life Sciences, provides bulk diagnostic enzyme manufacturing and fermentation services. EKF Life Sciences specializes in producing enzymes, including Salicylate Hydroxylase and Beta-Hydroxybutyrate Dehydrogenase. Its products include Quo-Test A1c, Biosen, Quo-Lab A1c, UltraCrit, DiaSpect, HemataStat II and Creamatocrit Plus. The company operates in Germany, the United States, Russia and the United Kingdom.
See Also
What is EKF Diagnostics Holdings PLC's Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
398k
GBP
Based on the financial report for Dec 31, 2025, EKF Diagnostics Holdings PLC's Current Portion of Long-Term Debt amounts to 398k GBP.
What is EKF Diagnostics Holdings PLC's Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
-27%
Over the last year, the Current Portion of Long-Term Debt growth was -5%. The average annual Current Portion of Long-Term Debt growth rates for EKF Diagnostics Holdings PLC have been -27% over the past three years , -7% over the past five years , and -27% over the past ten years .
